GOVX - GeoVax Labs, Inc.

1.71
0.120   7.018%

Share volume: 97,918
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$1.59
0.12
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 28%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
9.62%
1 Month
-33.72%
3 Months
353.46%
6 Months
145.09%
1 Year
-2.29%
2 Year
-20.47%
Key data
Stock price
$1.71
P/E Ratio 
0.00
DAY RANGE
$1.58 - $1.77
EPS 
-$2.70
52 WEEK RANGE
$0.12 - $4.40
52 WEEK CHANGE
-$6.56
MARKET CAP 
11.998 M
YIELD 
N/A
SHARES OUTSTANDING 
29.705 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
7.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$49,202
AVERAGE 30 VOLUME 
$136,440
Company detail
CEO: David A. Dodd
Region: US
Website: geovax.com
Employees: 10
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

GeoVax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV) and malaria.

Recent news